A5101412279- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- Inflammatory Biomarkers in Disease Prognosis
- Immune cells in cancer
- Colorectal Cancer Treatments and Studies
- Peptidase Inhibition and Analysis
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Renal cell carcinoma treatment
- Esophageal Cancer Research and Treatment
- Parathyroid Disorders and Treatments
- Gastric Cancer Management and Outcomes
- Ferroptosis and cancer prognosis
- Colorectal and Anal Carcinomas
- Lung Cancer Treatments and Mutations
- Medical Imaging and Pathology Studies
- Protein Degradation and Inhibitors
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Multiple Myeloma Research and Treatments
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Immune Response and Inflammation
- Biosimilars and Bioanalytical Methods
- Genetic factors in colorectal cancer
Beijing Chao-Yang Hospital
2016-2025
Capital Medical University
2016-2025
Beijing Shijitan Hospital
2015
Dalian Medical University
2000
Second Affiliated Hospital of Dalian Medical University
2000
Myeloid-derived suppressor cells (MDSCs) are key player in mediating systemic immunosuppression, and their accumulation expansion the periphery tumor have been iteratively observed patients with various types of cancer. It has reported that CD14+HLA-DR−/low MDSCs increased hepatocellular carcinoma (HCC) patients; however, clinical significance MDSC alteration HCC after treatment is poorly studied. In this study, we examined frequency 92 patients, 14 chronic liver disease without HCC, 22...
Esophageal squamous cell carcinoma (ESCC) is the most common type of esophageal cancer and seventh prevalent cause cancer-related death worldwide. Tumor microenvironment (TME) has been confirmed to play an crucial role in ESCC progression, prognosis, response immunotherapy. There a need for predictive biomarkers TME-related processes better prognosticate outcomes.To identify novel gene signature linked with TME predict prognosis ESCC.We calculated immune/stromal scores 95 samples from The...
Abstract Bombyx mori Tryptophanyl-tRNA synthetase ( BmWARS ) belongs to the family of Ic-like aminoacyl-tRNA synthetases (aaRSs), whose specific recognition substrate Trp, tRNA, maintains fidelity protein synthesis. In this study, was cloned and characterized from midgut silkworm, , resulting in an open reading frame (ORF) with a full length 1,149 bp, which can encode 382 Aa. is localized cytoplasm, expressed all tissues higher expression testis, ovary, silk gland malpighian tubule. The...
Background Elevated plasma fibrinogen (Fbg) levels contribute to tumor progression and metastasis; however, limited research on Fbg in small cell lung cancer (SCLC) has been conducted. This study evaluated the prognostic value of patients with SCLC. Methods Data level, clinical features, overall survival were retrospectively collected. Kaplan–Meier estimates log‐rank tests used analyze relationship between level survival. Multivariate analyses performed determine independent factors....
Neutrophils play a critical role in the initiation and maintenance of intestinal inflammation. However, conventional neutrophil‐targeted therapies can impair normal host defense. Tanshinone IIA has been recently revealed to act directly on neutrophils. Hence, we aimed at investigating whether protect against experimental colitis through modulation We induced C57BL/6 mice by giving 3% dextran sulfate sodium (DSS) orally, meanwhile, treated daily with intraperitoneally. The severity was...
Dysregulation of C‑Type Lectin Domain Family 3 Member B (CLEC3B) in serum or tumor tissues has been reported patients with various cancer types. However, the expression and function CLEC3B clear cell renal carcinoma (ccRCC) remain unknown. To examine ccRCC, The Cancer Genome Atlas (TCGA) Gene Expression Omnibus (GEO) databases were examined to determine at transcriptional level it was demonstrated that mRNA significantly downregulated ccRCC compared normal (P<0.0001 P=0.0392 TCGA GEO...
HLX04 is a proposed biosimilar of bevacizumab. This phase III study aimed to evaluate the efficacy, safety, and immunogenicity compared with reference bevacizumab in combination XELOX or mFOLFOX6 as first-line treatment for recurrent/metastatic colorectal cancer (CRC). In this double-blind, parallel-group study, patients were randomized 1:1 receive (7.5 mg/kg every 3 weeks when combined XELOX; 5 2 mFOLFOX6). The primary endpoint was progression-free survival rate at week 36 (PFSR36w) per...
Intrahepatic cholangiocarcinoma (ICC) is a malignant carcinoma with high rate of mortality. The current treatment ineffective poor survival time. Therefore, there an urgent need for effective therapeutic drug regimens. multi-target tyrosine kinase inhibitor (TKI) anlotinib has been approved treating non-small cell lung cancer (NSCLC); however, the combined regimen ICC not investigated yet. This study aims to investigate inhibitory effect and mechanism gemcitabine combination treatment.Two...
Abstract Background Cholangiocarcinoma (CCA), characterized by high heterogeneity and extreme malignancy, has a poor prognosis. Doublecortin-like kinase 1 (DCLK1) promotes variety of malignant cancers in their progression. Targeting DCLK1 or its associated regulatory pathways can prevent the generation deterioration several malignancies. However, role CCA progression molecular mechanisms remain unknown. Therefore, we aimed to investigate whether how contributes Methods The expression...
Overwhelming evidence from leukemia research has shown that the clonal population of neoplastic cells exhibits marked heterogeneity with respect to proliferation and differentiation. There are rare stem within leukemic possess extensive self-renewal capacity not found in majority cells. These necessary sufficient maintain leukemia. While hematopoietic cell (HSC) origin CML was first suggested over 30 years ago, recently CML-initiating beyond HSCs also being investigated. We have previously...
Pathological stage III/N2 non-small cell lung cancer (NSCLC) is heterogeneous, and the optimal prognostic marker for survival remains unclear in Chinese patients. The aim of present study was to assess value clinicopathologic features excision repair cross-complementing group-1 (ERCC1) resected p-stage NSCLC patients that received cisplatin-based adjuvant chemotherapy.Clinical data concerning 115 with histopathologically confirmed who underwent a complete resection were reviewed...
To investigate the relationship between pretreatment plasma D-dimer levels and survival in Chinese patients with small cell lung cancer (SCLC).This retrospective study enrolled 82 SCLC treated at Beijing Chaoyang Hospital, Capital Medical University, from January 2012 to 2015. All were followed up. Associations measured by immunoturbidimetric assay clinical outcomes analyzed Kaplan-Meier multivariate analyses, using a cut-off level of 0.55 mg/L fibrinogen equivalent units (FEU).Median...
Abstract Numerous studies and clinical trials have shown that immune checkpoint inhibitors can effectively prevent tumor growth metastasis in esophageal squamous cell carcinoma (ESCC) patients. In this study, we aimed to evaluate the anti-tumor effects of PD-1 antibody preventive treatment patients with early stages ESCC as well high-grade intraepithelial neoplasia (HGIN). We first established an model using C57BL/6J mice treated chemical carcinogen 4- NQO observed lesions at different time...
ERBB2 amplification is one of the most important and mature targets for HER2-targeted drug therapy. Somatic mutations in tyrosine kinase domain have been studied extensively, play a role response to anti-HER2 therapy among different cancer types. However, fusion has not got attention its relevance unclear. We comprehensively characterized fusions from next-generation sequencing (NGS) data between May 2018 October 2021 32,131 various solid tumors. Among tumors, 0.28% harbored fusions, which...
Abstract Numerous studies have shown that the blood of cancer patients are generally in hypercoagulable statement. The aim present research is to study relationships plasma fibrinogen (Fbg) levels with clinicopathological stages (CS) and tumor markers non-small cell lung (NSCLC). Baseline information, Fbg levels, CS, expression level were collected from medical records retrospectively. Unitary linear regression was used analyze between continuous variables Fbg, multiple categorical Fbg....
Bortezomib is used to treat patients with multiple myeloma. It primarily metabolized by the enzyme cytochrome P450 (CYP). Variations in capacity of bortezomib metabolism affect treatment outcomes and side‑effects experienced patients. In present study, polymorphisms CYP3A4 CYP2C19 genes were analyzed polymerase chain reaction 56 newly‑diagnosed The included c.681G>A, c.636G>A c.-806C>T CYP2C19. gene was sequenced after amplification classified into normal mutant types. Associations between...
Personalized medicine has become essential in the treatment of lung cancer. However, cancer-related gene expression profiles non-small cell cancer (NSCLC) patients have not been elucidated. In this study, correlation between and clinicopathological characteristics was investigated NSCLC patients. A total 95 were enrolled study. The mRNA levels 14 genes assessed by multiplex branched DNA liquidchip (MBL) technology data on 9 collected simultaneously. investigated. Out parameters, 6 associated...
To investigate the significance of lymphocyte-to-monocyte ratio (LMR) combined with carbohydrate antigen (CA) 19-9 for predicting postoperative recurrence colorectal cancer (CRC) in patients type II diabetes.We conducted a retrospective analysis 106 stage II-III CRC and diabetes. Their clinical indexes such as LMR CA19-9 were collected, followed up 5 years.The level was 119.7 U/ml at baseline relapsed group, while this 24.81 non-relapsed group (p = 0.001). On contrary, 5.10 2.57 < 0.001),...
The aim of this study was to analyse changes in the lymphocyte subgroups non-small cell lung cancer (NSCLC) patients before and during four cycles chemotherapy.NSCLC (n = 32) who were undergoing their initial chemotherapy or had finished final ≥ three months ago enrolled. divided into demographic subgroups. Lymphocyte 13) examined via flow cytometry (9 time points).NSCLC exhibited overall decreases chemotherapy. Most increased slightly second cycle but decreased afterwards compared with...